- |||||||||| doxorubicin hydrochloride / generics
Journal: Anthracyclines Suppress Both NADPH Oxidase- Dependent and -Independent NETosis in Human Neutrophils. (Pubmed Central) - Sep 11, 2019 The dexrazoxane, a cardioprotective agent, used for limiting the side effects of anthracyclines, neither affect NETosis nor alter the ability of anthracyclines to suppress NETosis. Hence, at correct doses, anthracyclines together with dexrazoxane could be considered as a therapeutic candidate drug for suppressing unwanted NETosis in NET-related diseases.
- |||||||||| Neulasta (pegfilgrastim) / Amgen, Kyowa Hakko Kirin, Roche
Clinical, Journal: Pegfilgrastim-induced fatigue and leukocytosis improved following dose reduction in a young patient with breast cancer: A case report. (Pubmed Central) - Sep 3, 2019 ...The patient was diagnosed with cT2N1M0, stage IIB triple-negative breast cancer and underwent four cycles of DD chemotherapy with epirubicin plus cyclophosphamide, followed by four cycles of docetaxel (DTX) every 2 weeks preoperatively, with 3.6 mg pegfilgrastim administered subcutaneously on day 3 of each cycle...No patients other than the one presented herein experienced leukocytosis during chemotherapy. Although this was a rare complication, a dose of 1.8 mg pegfilgrastim was effective in palliating the patient's symptoms and preventing DD chemotherapy discontinuation.
- |||||||||| paclitaxel / Generic Mfg.
Clinical, Journal: Effective Neo-Adjuvant Chemotherapy and Hormonal Therapy for Invasive Micro-Papillary Carcinoma of the Breast-Two Case Reports (Pubmed Central) - Aug 30, 2019 ...The patient underwent 4 courses of EC(epirubicin 90mg/ m2, cyclophosphamide 600 mg/m2), followed by 4 courses of triweekly docetaxel and nab-paclitaxel chemotherapy...Pre-operative treatment consisted of letrozole(2.5mg/day)from May 2013 and hormone therapy for 6 months...Histopathologically, no remnant of IMPC component was observed apart from an 11mm papillo-tubular carcinoma. In spite of the fact that IMPC is considered highly malignant, pre-operative chemotherapy and hormonal therapy may be effective.
- |||||||||| pegylated liposomal doxorubicin / Generic mfg., cyclophosphamide / Generic mfg., epirubicin / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients (clinicaltrials.gov) - Aug 22, 2019 P2, N=254, Active, not recruiting, With G-CSF support, epirubicin 85-90 mg/m(2) is appropriate tolerance dose for Chinese early breast cancer patients with high recurrence risk. Recruiting --> Active, not recruiting | Trial completion date: Aug 2018 --> May 2023 | Trial primary completion date: Jul 2018 --> Oct 2019
- |||||||||| epirubicin / generics
Journal: Cytotoxic Anthracycline Metabolites from a Recombinant Streptomyces. (Pubmed Central) - Aug 17, 2019 These compounds exhibited cytotoxicity against a panel of human cancer cell lines. Significantly, compounds 4 and 13 displayed pronounced activity against HCT-116 as characterized by IC values of 0.3 and 0.2 μM, respectively; these IC values are comparable to that of the positive control epirubicin.
- |||||||||| metformin / generics, doxorubicin hydrochloride / generics
Review, Journal, IO Biomarker: Formononetin: A Review of Its Anticancer Potentials and Mechanisms. (Pubmed Central) - Aug 14, 2019 Co-treatment with other chemotherapy drugs such as bortezomib, LY2940002, U0126, sunitinib, epirubicin, doxorubicin, temozolomide, and metformin enhances the anticancer potential of both formononetin and the respective drugs through synergistic effect. Compiling the evidence thus far highlights the potential of formononetin to be a promising candidate for chemoprevention and chemotherapy.
- |||||||||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment closed, Metastases: MATEO: Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer (clinicaltrials.gov) - Aug 7, 2019 P2, N=400, Active, not recruiting, 2D and 3D Echocardiography assessment and 2D Strain analysis did not show subclinical myocardial dysfunction in adult survivors who received dexrazoxane-anthracyclines in childhood. Recruiting --> Active, not recruiting
- |||||||||| dexamethasone / generics, cyclophosphamide intravenous / generics
Clinical, Journal: Multiple myeloma with onset of pancreas involvement: A case report. (Pubmed Central) - Aug 2, 2019 This case demonstrates that pancreatic involvement, digestive system neoplasm, and amyloidosis-related clinical features may be the earliest manifestations of multiple myeloma. For these patients, an intensive chemotherapy regimen may be a possible treatment approach.
- |||||||||| Hervelous (trastuzumab biosimilar) / Hanwha Solutions, Alvogen, Prestige BioPharma, Mundipharma, Dr. Reddy's
Trial primary completion date: TROIKA: A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin (clinicaltrials.gov) - Aug 1, 2019 P3, N=500, Active, not recruiting, Therefore, it may be argued that methotrexate may be a more effective anticancer drug than all other drugs used in this study against the multi drug resistance that will occur during chemotherapy. Trial primary completion date: Sep 2019 --> Dec 2019
- |||||||||| fluorouracil / generics, cyclophosphamide intravenous / generics
Biomarker, Clinical, Journal, BRCA Biomarker: Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy. (Pubmed Central) - Jul 31, 2019 Endocrine therapy consisted of tamoxifen (±GnRH agonists)...AMH levels were similar between BRCA-mutated and BRCA-negative patients at baseline (1.94 vs. 1.66 μg/L, p = 0.53), 1 year (0.09 vs. 0.06 μg/L, p = 0.39) and 3 years (0.25 vs. 0.16 μg/L; p = 0.43) after diagnosis. In breast cancer patients receiving FEC chemotherapy, adding D appeared to negatively impact on their ovarian reserve in the short-term; no further detrimental effect was observed for endocrine therapy use and presence of a deleterious germline BRCA mutation.
- |||||||||| Abraxane (albumin-bound paclitaxel) / Celgene, Otsuka
Clinical, Journal: Feasibility Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (150 mg/m) Followed by Fluorouracil, Epirubicin, and Cyclophosphamide Therapy as Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer. (Pubmed Central) - Jul 17, 2019 Approximately one-third of sporadic breast tumors show a high HRD score, indicating the presence of homologous recombination dysfunction, and they are characterized by biologically aggressive phenotypes, most commonly in the TNBC subtype, and less sensitive to P-FEC. Our study showed that weekly nab-paclitaxel 150 mg/m3q4w followed by FEC as neoadjuvant regimen might be sufficient in efficacy, although with a relatively high severe adverse event occurrence rate.
- |||||||||| Herceptin (trastuzumab) / Roche
Clinical, Journal: Maintaining Dose Intensity of Adjuvant Chemotherapy in Older Patients With Breast Cancer. (Pubmed Central) - Jul 17, 2019 Our findings suggest that patients aged ≥ 65 years with ESBC can maintain an optimal RDI with modern chemotherapy regimens. Appropriate geriatric assessment and the use of supportive measures such as G-CSF could better assist select groups to maintain an optimal dose intensity.
|